CPMV — Mosaic ImmunoEngineering Inc.
—
OTC ·
Health Care ·
Biotechnology ·
CIK 836564 ·
Last close
$0.06
Market Cap
$441.8K
52W High
$1.05
52W Low
$0.05
ADV30
107
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -156,721 | -177,496 | 3,278 | 26 | 7,832,145 |
| Mar 2026 | 0 | — | -154,802 | -175,351 | 9,828 | 72 | 7,661,199 |
| Dec 2025 | 0 | — | -148,133 | -169,137 | 19,882 | 3,622 | 7,495,902 |
| Sep 2025 | 0 | — | -144,358 | -165,361 | 55,298 | 31,761 | 7,362,181 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-85,859
Investing CF
$0
Financing CF
$130,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.09
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-9,701,517
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-596,144
Pretax Income TTM
$-679,477
Interest Exp TTM
$83,333
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -616,119 | -687,846 | 19,882 | 7,495,902 | -7,476,020 | -111,397 |
| Dec 2024 | 0 | -879,655 | -921,983 | 141,611 | 6,929,785 | -6,788,174 | -241,159 |
| Dec 2023 | 0 | -1,399,768 | -1,008,235 | 179,533 | 6,050,591 | -5,871,058 | -497,467 |
| Dec 2022 | 0 | -2,627,522 | -2,380,870 | 261,277 | 5,146,035 | -4,884,758 | -690,129 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CERO | CERO THERAPEUTICS HOLDINGS, INC. | $787.9K | $0.01 | — |
| AGTX | Agentix Corp. | $801.3K | $0.02 | — |
| SCNI | Scinai Immunotherapeutics Ltd. | $996.0K | $1.47 | — |
| GPLB | Green Planet Bio Engineering Co. Ltd. | $176.1K | $0.01 | — |
| SLXN | Silexion Therapeutics Corp | $1.38M | $0.25 | — |
Recent Insider Activity
No insider activity indexed for this ticker.